Novo Nordisk shares surged on the results of a new obesity-drug study Friday. The Danish pharmaceutical giant behind Ozempic ...

The Danish drug company said an experimental weight-loss shot helped patients lose over one-fifth of their bodyweight. Novo's U.S. and [Europe-listed s ...

Existing home sales climbed 2.2% in December to a seasonally adjusted annual rate of 4.24 million, according to the National ...

Apple stock has tumbled at the start of the year. BofA Securities advises investors to stay the course but joined a chorus of Wall Street voices expressing concern over flagging iPhone demand. The ...

STOCKSTOWATCHTODAY BLOG Alphabet has an Nvidia -like business inside it. It could be the most valuable part of the internet search giant. Some investors might not know that Alphabet has an AI chip ...

Novo Nordisk (NVO) shares are surging by nearly 11% in Friday's pre-market trading after releasing positive early trial results for the company's injectable GLP-1 weight-loss drug, amycretin. Yahoo ...

Novo Nordisk said a Phase 1b/2a clinical trial of amycretin, which activates both the GLP-1 and amylin receptors to help manage blood sugar and weight, achieved weight loss of 22% on a 20 milligram ...

Allurion stock soars on weight-loss therapy update. Stardust Power breaks ground on Oklahoma lithium refinery. OpenAI ...

The most recent trading session ended with Novo Nordisk (NVO) standing at $80.57, reflecting a -0.57% shift from the previouse trading day's closing. This change lagged the S&P 500's 0.61% gain on the ...

Beam Therapeutics shows promise in gene therapy for sickle cell disease, but it also has high risks and market expectations.

Viking (VKTX) is in the midst of a phase 2a dosing trial of its oral obesity drug VK2735, with a data readout expected in the second half of the year. The company is expected to launch a phase 3 trial ...